Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of albumin-bound paclitaxel (nab-paclitaxel) and pegylated liposomal doxorubicin (PLD). Albumin-bound paclitaxel is a solvent-free, nanoparticle formulation of paclitaxel that promotes microtubule assembly and stabilizes them against depolymerization, thereby inhibiting cell division. Pegylated liposomal doxorubicin is an anthracycline antibiotic encapsulated in liposomes with surface-bound polyethylene glycol (PEG), which extends its circulation time and enhances tumor accumulation. Doxorubicin works by intercalating DNA and inhibiting topoisomerase II, leading to DNA strand breaks and apoptosis. This specific combination has been investigated by the Shaanxi Provincial Cancer Hospital as a treatment for platinum-resistant recurrent gynecological cancers, including ovarian cancer, fallopian tube carcinoma, and primary peritoneal carcinoma, aiming to improve efficacy while managing the toxicity profiles associated with traditional taxane and anthracycline therapies.
- Brand names
- Abraxane + DoxilAbraxane + Caelyx
- Other names
- nab-paclitaxel + pegylated liposomal doxorubicinnab-paclitaxel + PLDnanoparticle albumin-bound paclitaxel + pegylated liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNA
Beyond the preview
Go deeper on albumin-bound paclitaxel + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + pegylated liposomal doxorubicin.